Back to search results

LARC Robot for Kidney Stone Removal

This study is testing a new robotic system called LARC Robotic System (Micromate™ Version 3.0) to help doctors more accurately reach the kidney during surgery to remove large kidney stones. This surgery, called percutaneous nephrolithotomy (PCNL), is for people with large or difficult-to-remove kidney stones. The LARC robot uses live X-ray images to guide the doctor in placing a needle directly into the kidney, which could avoid needing a separate procedure beforehand. The study is looking to see how many people are stone-free within 30 days after the procedure and how often the procedure is successful. You may be able to join if you are 18 or older and have kidney stones larger than 2 cm, staghorn calculi, lower pole stones less than 2 cm, certain anatomical abnormalities, or stones that haven't responded to other treatments. The study plans to enroll 45 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 45 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will check if you are stone-free within 30 days after the procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07211555

The LARC Robot Simplifies Renal Access In Percutaneous Nephrolithotomy

Not Yet Recruiting
NAAges 18+InterventionalTreatment
AdventHealth
~45 participants
Updated 2025-10-08 on ClinicalTrials.gov
What's tested:LARC Robotic System (Micromate™ Version 3.0)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Stone-Free Rate (SFR)
Measured over Within 30 days post-procedure
+1 more outcome measured

Conditions

Renal Stone Disease
Kidney Calculi
Refractory Kidney Stones
Kidney Stones

Explore related trials

Nephrolithiasis

Where it's being run

1 sites across 1 states
Florida1

Who to contact

Petronio Senior Clinical Research Operations Manager, MHA
[email protected]
407-303-3603
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Kidney stones larger than 2 cm
Staghorn renal calculi
Lower pole stones less than 2 cm
Anatomical abnormalities that reduce the likelihood of spontaneous stone fragment passage, such as:
Horseshoe kidney
Calyceal diverticulum
Ectopic or dystopic kidney
Stones that are refractory to prior treatment (e.g., ESWL or ureteroscopy)
Suspected malignant tumors or masses located in the planned renal access tract

Exclusion

Pregnancy
Active urinary tract infection (UTI) or untreated sepsis
Known bleeding disorders or uncorrectable coagulopathy despite medical management
Use of anticoagulant medications (e.g., warfarin, heparin, or DOACs) that cannot be safely discontinued
Allergy to contrast media that cannot be pre-medicated or managed
Severe cardiopulmonary comorbidities that contraindicate anesthesia or PCNL
Inability to provide informed consent
Participation in another investigational study that may interfere with study outcomes

What this trial measures

  • Stone-Free Rate (SFR)Within 30 days post-procedure

    Proportion of participants with no residual kidney stones larger than 4 mm, as determined by imaging (non-contrast CT, KUB X-ray, or renal ultrasound).

  • Procedure Success RateDuring procedure (Day 0)

    Proportion of procedures in which the urologist was able to successfully obtain renal access and complete the PCNL using the LARC robotic system, without converting to manual or radiologist-assisted access.